Production (Stage)
Alnylam Pharmaceuticals, Inc.
ALNY
$317.47
$2.530.80%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 31.38% | 24.92% | -560.61% | 74.39% | 52.18% |
| Total Depreciation and Amortization | 170.11% | -175.99% | 9.50% | 82.67% | 171.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 69.10% | -14.00% | -41.14% | 108.74% | 7.56% |
| Change in Net Operating Assets | -192.47% | -341.50% | 162.33% | 54.54% | -303.51% |
| Cash from Operations | -24.99% | -316.58% | -64.80% | 252.31% | -173.59% |
| Capital Expenditure | 1.36% | -116.94% | 47.72% | 38.19% | 15.26% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 380.12% | -68.15% | -162.10% | 176.78% | 75.75% |
| Cash from Investing | 315.02% | -74.91% | -189.13% | 150.19% | 71.90% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 36.07% | -66.42% | -18.63% | 413.47% | -16.30% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | 0.00% | -311.93% | -142.01% | -63.38% |
| Cash from Financing | 42.22% | -69.83% | -21.86% | 354.83% | -26.30% |
| Foreign Exchange rate Adjustments | 181.40% | -214.43% | 583.75% | 68.61% | -191.23% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 140.04% | -201.94% | -54.17% | 320.09% | 40.92% |